Ligand-based and structured-based in silico repurposing approaches to predict inhibitors of sars-cov-2 mpro protein

5Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a coronavirus that causes the pandemic Coronavirus Disease 2019 (COVID-19). There is no current specific treatment for this new coronavirus. In this study, we employed a virtual screening repurposing strategy to search for potential SARS-CoV-2 Mpro inhibitors. The databases PDB, ChEMBL, BindingDB and DrugBank were queried with several filtering steps based on ligand-based and structure-based approaches. As a result, we obtained 58 molecules (37 from ChEMBL and 21 from DrugBank) that potentially inhibit SARS-CoV-2 Mpro. These molecules have on their chemical structure functional groups that favor stronger docking scores than the inhibitor N3. Several of these molecules are reported experimentally as SARS-CoV Mpro inhibitors. Hence, a combined virtual screening strategy allowed finding chemical compounds with a high potential for the inhibition of SARS-CoV-2 Mpro.

Cite

CITATION STYLE

APA

Juárez-Saldívar, A., Lara-Ramírez, E. E., Reyes-Espinosa, F., Paz-González, A. D., Villalobos-Rocha, J. C., & Rivera, G. (2020). Ligand-based and structured-based in silico repurposing approaches to predict inhibitors of sars-cov-2 mpro protein. Scientia Pharmaceutica, 88(4), 1–14. https://doi.org/10.3390/scipharm88040054

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free